RT Journal Article
SR Electronic
T1 Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study
JF RMD Open
JO RMD Open
FD EULAR
SP e001519
DO 10.1136/rmdopen-2020-001519
VO 7
IS 1
A1 Roberta Ramonda
A1 Mariagrazia Lorenzin
A1 Antonio Carriero
A1 Maria Sole Chimenti
A1 Raffaele Scarpa
A1 Antonio Marchesoni
A1 Ennio Lubrano
A1 Carlo Salvarani
A1 Alberto Cauli
A1 Angelo Semeraro
A1 Leonardo Santo
A1 Augusta Ortolan
A1 Andrea Doria
A1 Elena Fracassi
A1 Giulia Virelli
A1 Marco Masia
A1 Rosalinda Fanizzi
A1 Elisa Visalli
A1 Giorgio Amato
A1 Antonio Carletto
A1 Rosario Foti
A1 ,
YR 2021
UL http://rmdopen.bmj.com/content/7/1/e001519.abstract
AB Objectives To evaluate in a multicentric Italian cohort of patients with psoriatic arthritis (PsA) on secukinumab followed for 24 months: (1) the long-term effectiveness and safety of secukinumab, (2) the drug retention rate and minimal disease activity (MDA), (3) differences in the outcomes according to the biological treatment line: biologic-naïve patients (group A) versus multifailure (group B) patients.Methods Consecutive patients with PsA receiving secukinumab were evaluated prospectively. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were collected. Disease activity/functional/clinimetric scores and biochemical values were recorded at baseline (T0), 6(T6), 12(T12) and 24(T24) months. Effectiveness was evaluated overtime with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of drug-discontinuation and MDA at T6. Infections and adverse events were recorded.Results 608 patients (41.28% men; mean (SD) age 52.78 (11.33)) were enrolled; secukinumab was prescribed as first-line biological treatment in 227 (37.34%) patients, as second (or more)-line biological treatment in 381 (62.66%). Effectiveness of secukinumab was shown with an improvement in several outcomes, such as Ankylosing Spondylitis Disease Activity Score (T0=3.26 (0.88) vs T24=1.60 (0.69) ;p=0.02) and Disease Activity Index for Psoriatic Arthritis (T0=25.29 (11.14) vs T24=7.69 (4.51); p<0.01). At T24, group A showed lower Psoriasis Area Severity Index (p=0.04), erythrocyte sedimentation rate and C reactive protein (p=0.03 ;p=0.05) and joint count (p=0.03) compared with group B. At T24, MDA was achieved in 75.71% of group A and 70.37% of group B. Treatment was discontinued in 123 (20.23%) patients, mainly due to primary/secondary loss of effectiveness, and in 22 due to adverse events. Retention rate at T24 was 71% in the whole population, with some difference depending on secukinumab dosage (p=0.004) and gender (p=0.05).Conclusions In a real-life clinical setting, secukimumab proved safe and effective in all PsA domains, with notable drug retention rate.